Oncology and Hematology - Prova Education

Episodes 1-16 of 118

Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CME/CE
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
0.25 credits
- Neal Shore, MD, FACS
- Sarah Psutka, MD, MS
0.25 credits
First Results From Cohort 4 of the SunRISe-1 Trial
First Results From Cohort 4 of the SunRISe-1 Trial
Oncology and Hematology
First Results From Cohort 4 of the SunRISe-1 Trial
Trial in Progress: Phase 3 MoonRISe-3 Study
Trial in Progress: Phase 3 MoonRISe-3 Study
Oncology and Hematology
Trial in Progress: Phase 3 MoonRISe-3 Study
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results 
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results 
Oncology and Hematology
SunRISe-1: 1-Year Durability and Patient-Reported Outcomes Results 
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Collaborative Insights to Solve the Puzzle of Bladder Cancer
CME/CE
Collaborative Insights to Solve the Puzzle of Bladder Cancer
1.00 credit
- Daniel P. Petrylak, MD
- Elizabeth R. Plimack, MD, MS, FASCO
- Evan Y. Yu, MD
1.00 credit
Personalizing Care Within the RCC Treatment Paradigm
Personalizing Care Within the RCC Treatment Paradigm
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credit
- Eric Jonasch, MD
- Brad McGregor, MD
- Ulka Vaishampayan, MBBS
1.00 credit
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
MinuteCE®
Optimizing Ovarian Function Suppression in Hormone Receptor-Positive Breast Cancer: Best Practices for the Community Clinician
0.50 credits 4 episodes
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 credits 4 episodes
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
0.50 program credits
- Sandra Swain, MD
- Virginia Kaklamani, MD
0.50 program credits
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
CME/CE
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
0.50 credits
- Javier Cortes, MD, PhD
- Hope S. Rugo, MD, FASCO
0.50 credits
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
0.25 credits
0.25 credits
Molecular Profiling for HER2+ Advanced Solid Tumors
Molecular Profiling for HER2+ Advanced Solid Tumors
CME/CE
Molecular Profiling for HER2+ Advanced Solid Tumors
1.00 credit
- Eric Van Cutsem, MD, PhD
- David SP Tan, MBBS, PhD, PRCP
- James Chih-Hsin Yang, MD, PhD
- Kathleen Moore, MD, MS, FASCO
1.00 credit
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
0.25 credits
- Jeffrey V. Matous, MD
- Donna Catamero, NP
0.25 credits
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CE
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
0.25 credits
- Jonathan Leventhal, MD
- Shahnaz Singh-Kandah, NP
0.25 credits

Prev
1
2
3
…
7
8
Next

1/6